Welcome to our dedicated page for Pacific Biosc SEC filings (Ticker: PACB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The PacBio (Pacific Biosciences of California, Inc., NASDAQ: PACB) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including current reports, annual and quarterly reports, and other documents filed with the U.S. Securities and Exchange Commission. These filings offer detailed information on PacBio’s financial performance, risk factors, and business operations related to its advanced sequencing solutions and integrated genetic analysis platforms.
For a life science technology company like PacBio, investors often look to annual reports on Form 10-K and quarterly reports on Form 10-Q for discussions of revenue from instruments, consumables, and services, as well as commentary on product adoption, research collaborations, and regional trends. Current reports on Form 8-K, such as the November 5, 2025 filing that furnished a press release on third quarter 2025 financial results, provide timely updates on material events and earnings announcements.
Stock Titan enhances these SEC filings with AI-powered summaries designed to explain key sections in clear language. Instead of reading full-length documents unaided, users can rely on AI-generated highlights to understand topics such as PacBio’s use of GAAP and non-GAAP financial measures, its description of sequencing platforms and applications, and management’s discussion of business risks and opportunities.
In addition to periodic reports and 8-Ks, investors may also review proxy statements and, where applicable, insider transaction reports on Form 4 to understand equity-related activity by officers and directors. With real-time updates from EDGAR and AI-assisted insights, this PACB filings page helps users quickly locate and interpret the regulatory information that PacBio provides about its operations in genomic sequencing and analytical laboratory instruments.
Mark Van Oene, Chief Operating Officer of Pacific Biosciences of California, Inc. (PACB), reported a routine sale of shares to cover tax withholding upon RSU vesting. The Form 4 discloses that on 08/18/2025 he disposed of 26,836 shares at a weighted average sale price of $1.311 per share (sale prices ranged from $1.30 to $1.32). After the transaction he beneficially owns 1,920,035 shares. The filing explains the shares were automatically sold to satisfy tax withholding obligations related to restricted stock unit vesting. The Form 4 was signed by an attorney-in-fact on 08/20/2025.
Pacific Biosciences (PACB) filed a Form 144 reporting a proposed sale of 26,836 restricted common shares acquired on 08/15/2025. The filing lists the broker as Morgan Stanley Smith Barney LLC and shows an aggregate market value of $35,173.95 with an approximate sale date of 08/18/2025 on NASDAQ. The issuer's total shares outstanding are reported as 300,370,611. The filer indicates there were no securities sold in the past three months for the same account and signs the standard representation that they are not aware of undisclosed material adverse information.
Multiple related parties reported material holdings in Pacific Biosciences (PACB). Madrone Opportunity Fund directly holds 16,762,216 shares (5.6% of class) and Shimoda Holdings directly holds 3,500,000 shares (1.2%). Gregory Boyd Penner is reported as an individual with aggregate beneficial ownership of 20,262,216 shares (6.8% of class), reflecting his roles across the filing entities.
The filing discloses that the reported shares carry shared voting and shared dispositive power among the reporting persons and that the percentage figures are calculated using 300,084,685 shares outstanding as the denominator. The reporting persons expressly disclaim status as a "group."
Edmond de Rothschild Asset Management (France & Luxembourg) and Edmond de Rothschild Fund submitted Amendment No. 1 to Schedule 13G for Pacific Biosciences of California, Inc. (PACB), triggered by the 30 Jun 2025 measurement date.
- Aggregate shares: 13.37 million (EDRAM France) and 12.08 million (each Luxembourg entity).
- Ownership: 4.5 % of outstanding common stock for EDRAM France; 4.0 % for EDRAM Luxembourg and EdR Fund—placing all filers below the 5 % reporting threshold.
- Voting/Dispositive power: Shared voting & dispositive authority over 12.08 million shares; sole dispositive power limited to 1.28 million shares; no sole voting power.
- The filers certify the stake is held in the ordinary course of business as passive investment managers, with no intent to influence control.
The filing confirms continued, but sub-5 %, institutional support from a prominent European asset manager without signaling activist involvement.